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Abstract
A convergent synthesis of a novel estrogen receptor-targeted drug hybrid was developed based on
structures of the potent anti-proliferative mitomycin C and the steroidal anti-estrogen RU 39411.
The steroidal antiestrogen was prepared with an azido-triethylene glycoloxy linker while the
mitomycin C derivative (porfirimycin) incorporated a complementary 7-N-terminal alkyne. The
two components were ligated using the Huisgen [3 + 2] cycloaddition (“click”) reaction.
Preliminary biological assays demonstrated that the final hybrid compound retained both potent
anti-estrogenic and anti-proliferative activities.
Introduction
One approach for developing new chemotherapeutic agents involves conjugating two
biologically active compounds to make a single hybrid agent. In the field of hormone
responsive breast cancer, this strategy typically involves linking a potent estrogen receptor
(ER) targeting agent to a second component, such as an anti-metabolite, intercalating agent,
anti-mitotic, alkylating agent or metal chelating group.1–19 Unfortunately, the resultant
products from these efforts proved almost invariably to be less effective at each of its targets
than the separate, individual components. Typically one observes loss of ER affinity,
absence of cancer cell selectivity, and reduction in cytotoxicity associated with the
therapeutic moiety. The objective of this project was to overcome these problems by using a
different targeting strategy.
Several reviews have described the difficulties associated with designing bi-functional
hybrid drugs,20–27 but in the case of steroid receptor targeted hybrids, most of the problems
are related to a reliance on chemical transformations of readily available materials or easily
modified sites on those materials to prepare the target compounds. While attachment or
incorporation of functional groups at the 3-,6-,17α- or 17β-positions of estradiol is relatively
easy, an analysis of the crystal structures of agonist and antagonist complexes with estrogen
receptor-ligand binding domain (ER-LBD) suggests that such molecular modifications
seriously impair binding to the receptor28–31 (Fig. 1). Introduction of substituents at the 7α-
position of estradiol, such as those found in the anti-estrogen ICI-182,780 (faslodex),
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requires a few more steps, but leads to better retention of biological properties32,33 (Fig. 2).
However, the crystal structure of a complex using a similarly substituted ligand ICI-164,384
with ERα-LBD indicates that the steroidal scaffold is rotated around the 3–17 axis,
projecting the 7α-side chain into the 11β-pocket of the receptor and causing disorder
associated with helix-12.34
The position on the estradiol scaffold where structural modifications appear to be tolerated
best by the receptor is the 11β-site. A number of studies have demonstrated that 11β-alkyl,
alkenyl and aryl estradiols possess high ER binding affinity as well as a range of agonist and
antagonist properties.35–39 Because introduction of functional groups, alkyl or aryl, requires
a lengthy synthetic sequence from the estradiol 3-methyl ether or 11-oxo-estradiol starting
materials, relatively few research groups have exploited this route.40,41 Because we
developed expertise in preparing 11β-subsituted estradiols, selection of the 11β-(4-
substituted-oxyphenyl) estradiol scaffold as the ER targeting component of our hybrid
presented no significant problems.42,43 Of equal importance for drug delivery, the 11β-(4-
substituted-oxyphenyl) estradiols express high ER affinity and are potent antiestrogens.44 As
such, they would not elicit a proliferative effect in breast cancer cells.
The choice of mitomycin C as the second bioactive component, however, was based on its
clinical use for the treatment of advanced breast cancer.45–47 Although estradiol-mitomycin
C conjugates had been explored previously without success, largely because of
nonselectivity and toxicity, the two agents, antiestrogens plus mitomycin C, have been
considered for combination chemotherapy.48,49 Mitomycin C belongs to the class of
compounds that require metabolic activation, i.e., quinone reduction, prior to alkylation of
the DNA.50 It also displays a degree of sequence selectivity based upon its molecular
structure.51–54 It has also been demonstrated that structural modifications of the 7-amino
group retain anticancer and DNA alkylating activity, suggesting that incorporation of a
pendant group at that position would be tolerated55–59 (Fig. 3). As a result, we selected as a
preliminary target for synthesis which would incorporate all of the structural features we
considered would be essential in the hybrid agent – the 11β-(4-alkoxyaryl) estradiol for anti-
estrogenic effects, the 7-N-alkylamino mitomycin C for DNA binding, and the triethylene
glycol linker to span the two functional groups (Fig. 4).
Because the optimal individual structural components for the hybrid agent were yet to be
defined, our synthetic strategy needed to incorporate flexibility in the preparation of each
unit as well as in the ultimate assembly process. For the preparation of the steroidal
component we chose to use the Cu(I)-assisted 1,4-addition of aryl Grignard reagents to the
steroidal 5,10-α-epoxide rather than 1,2-addition to the 11-oxo steroids. The latter route may
be shorter but it is less effective for aryl than alkyl derivatives.60,61 The incorporation of the
protected phenolic group in the aryl moiety would subsequently permit the attachment of a
variety of substituents via Williamson or Mitsunobu chemistry. Oligoethylene glycols
provided several advantages as linkers. As bifunctional reagents, one can selectively
manipulate each terminus. One end could be linked to the phenolic group using either
Williamson (via tosylate) or Mitsunobu (via free alcohol) chemistry while the other could be
converted to the requisite coupling group, in our case an azide. The oligoethylene glycol
reagents are readily available and possess enhanced hydrophilicity which would compensate
for the highly non-polar character of the steroidal component. Our strategy for the
mitomycin C involved conversion to the more stable N-methylated aziridine derivative
(porfiromycin), as well as conversion to the 7-methoxy intermediate which would undergo
displacement by a variety of amines, in our case propargyl amine. Therefore, the two
synthetically demanding components, the steroid and the mitomycin C and their analogs, if
necessary, could be prepared separately and ultimately ligated using the Huisgen [3 + 2]
cycloaddition reaction.62,63 This procedure has the advantage that the individual
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components, the alkyne and the azido group are both chemically and biologically stable,
permitting the evaluation of each unit. Ultimately, the two components can be efficiently
coupled to form the disubstituted triazole that is chemically and biologically stable. In this
study we describe the preparation the target hybrid and initial evaluation as an ER ligand
and cytotoxic agent in two breast cancer cell lines.
Results and discussion
The synthesis of the estradiol component began with the estra-5-(10), 9(11)-diene 3,17
diethylene ketal 2, an intermediate that we had previously synthesized64,65 (Scheme 1).
Epoxidation using hydrogen peroxide and hexafluoroacetone under basic conditions gave
the 5,10-α-epoxide 3 and the 5,10-β-isomer 4 in a 76% isolated yield (3: 1 ratio). Cu(I)-
catalyzed 1,4- addition of 4-(trimethylsilyloxy) phenylmagnesium bromide followed by
dehydration and deketalization provided the 11β-(4-hydroxyphenyl)-estra-4,9-diene-3,17-
dione 5 in a 90% yield for the three steps.66–68 It should be noted that under these
conditions, the α-4-hydroxyphenyl steroid generated from the β-isomer 4 undergoes
isomerization to the more stable 11β-product 5. Stereochemistry is clearly established by the
upfield shift of the C-18 methyl group. Tosylation of triethylene glycol proceeded in high
yield to give the ditosylate derivative 669 which underwent Williamson ether synthesis with
the 4-hydroxyphenyl steroid 5. Subsequent displacement of the terminal tosylate group with
sodium azide in ethanol gave the azido-triethylene glycoloxyphenyl derivative 7 in 10%
isolated yield (two steps).70,71 Aromatization of the estradienedione with acetic anhydride-
acetyl bromide, acetate saponification and stereoselective borohydride reduction of the 17-
ketone gave the 11β-(4-azido-triethylene glycoloxyphenyl) estradiol intermediate 8 in 56%
isolated yield for the three steps.
Preparation of the mitomycin C component began with N-methylation of mitomycin C 9
with methyl iodide to give porfiromycin 10 in 61% yield72,73 (Scheme 2). Subsequent
hydrolysis of the quinone amine to the hydroxy derivative, followed by methylation with
diazomethane gave the intermediate methyl ether. The intermediate underwent the
displacement reaction with propargylamine to give the desired 7-(N-propargyl)-
porfiromycin 11 in 55% yield for the three steps. Modifications of the amination step and
combining the last three steps into a single pot method significantly improved the overall
yield.
Ligation was accomplished using the Huisgen [3 + 2]-cycloaddition reaction between the
terminal alkynyl and azido groups73–76 (Scheme 3). A slight modification of the
conventional method was used, resulting in an isolated yield of 81% for the antiestrogen-
mitomycin C hybrid 1, which was characterized by 1H-,13C-NMR and HRMS. Analysis
indicated a single cycloaddition product in which the two coupling moieties were 1,4- to one
another. None of the 1,5-isomer was detected by NMR.
Initial biological evaluation of hybrid 1 as an ERα-LBD targeting group used competitive
binding assays with estradiol.77–79 The hybrid compound 1 competitively displaced estradiol
from ERα-LBD with relative binding affinity (RBA) value of 7 ± 1%, compared to estradiol
100%. The intermediate azido-estradiol derivative 8, in the same assay system had an RBA
= 26 ± 9%, indicating that the presence of the additional mitomycin-C group at the terminus
of the linker did not have an adverse effect on ER-LBD binding. Antagonist activity for
hybrid 1 was determined using the induction of alkaline phosphatase in Ishikawa cells.80
The hybrid 1 did not stimulate the production of alkaline phosphatase at any dose level,
however, the compound potently blocked the stimulation caused by 1 nM estradiol. This is a
typical antiestrogenic (antagonist) response. The antiestrogenic effect was similar to that
shown by the azido-estradiol derivative 8 which was a potent antagonist (Ki = 2.4 ± 0.6
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nM). Again, the results demonstrated that the presence of the mitomycin C moiety did not
interfere with the receptor binding or the inhibition of the transcriptional response. The N-
propargyl-porfiromycin 11, as expected, exhibited very low binding affinity for ERα-LBD
(RBA = 0.3 ± 0.2%). Compound 11 did exhibit a low level of inhibition in the alkaline
phosphatase assay (Ki = 40 ± 4 nM) suggesting that at higher doses of the antibiotic analog,
that there may be some cytotoxic effects rather than anti-estrogenic action. Therefore, one of
the key criteria for a hybrid drug was achieved, namely the presence of the mitomycin
component did not compromise the affinity or efficacy of the ER-binding group.
The second series of biological assays evaluated the effect of the mitomycin moiety on
cellular proliferation of MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) breast
cancer cell lines.32,33 Control studies using mitomycin C indicated that it is marginally more
potent in the MCF-7 vs. the MDA-231 cell lines. Incorporation of the anti-estrogen moiety
linked through the triethylene glycol to the mitomycin C in hybrid 1 had little additional
effect compared to mitomycin C on the anti-proliferative response in the MCF-7 or MDA-
MB-231 cells. The hybrid was neither more potent than mitomycin C (IC50 in the low μM
range) nor more selective for the ER(+)-MCF-7 cells. The second criterion was also
achieved as the presence of the anti-estrogenic moiety in hybrid 1, did not interfere with the
biological activity of the cytotoxin. However, the last objective was not entirely successful
as the hybrid did not appear to achieve potentiation of the biological response or
enhancement of the cell selectivity via a ER-mediated effect. [Graphs of the cytotoxicity
assays are shown in the ESI†]
An examination of the crystal structures of anti-estrogens bound to the ERα-LBD suggests
that the substituent at the 11β-position of estradiol is functionally equivalent to the dialkyl-
aminoalkylphenyl group of the triarylethylene anti-estrogens (hydroxytamoxifen and
raloxifene). Therefore, the second oxygen of the linker occupies the same site as the amino
group in exerting its effect on helix-12 and specifically on aspartic acid-351.28,29,81
Essentially all atoms beyond that point are external to the receptor surface and should be
accessible for other interactions with either solvent or other proteins. Further interactions
with the surface of the estrogen receptor would be significant only if those interactions
provide complementary binding to the protein, and in this case, they do not appear to be
significant. As shown in this study, the addition of substituents beyond the second oxygen of
the triethylene glycoloxy group does not dramatically reduce binding (indicating low steric/
electronic demands) nor does it enhance binding (evidence of absence of complementary
interactions). Therefore, the triethylene glycoloxy group successfully provided a means for
tethering a second molecular component to the steroidal scaffold without compromising ER
binding. Regarding the mitomycin-C component, binding studies suggest that interactions of
the electrophilic methoxylated carbon and carbamoylated carbon with guanyl residues of
DNA (mono or bis alkylation) occur on one face of the MMC molecule. The amino
component associated with the benzoquinone moiety remains solvent accessible and
therefore should not provide additional interactions with the DNA.51–54,82 The data indicate
that there are relatively few differences in biological activity between mitomycin C and the
conjugated derivative 1 in their ability to induce an anti-proliferative response in MCF-7 and
MDA-MB-231 cell lines. Therefore, as with the ER binding, extended triethylene glycoloxy
moiety therefore did not participate in the alkylation events responsible for the anti-
proliferative effect. The apparent absence of synergy between the two groups suggests that
the individual components do not recruit the complementary protein/DNA targets and
therefore are not providing simultaneous binding.
†Electronic supplementary information (ESI) available: Biological assays and graphs/figures, and spectral data for intermediates and
final compound. See DOI: 10.1039/c2ob25902h
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Conclusions
In summary, we have described the synthesis of a steroidal anti-estrogen conjugated to the
therapeutic agent, mitomycin C, hybrid 1, in which both components retained their full
biological properties. The individual targeting and cytotoxic components were synthesized
separately and ligated by means of a heterobifunctional triethylene glycol derivative.
Binding and functional assays indicated that the antiestrogenic component, as well as the
intact hybrid 1, retained high affinity for ERα-LBD and possessed potent antiestrogenic
activity in ER-responsive cells. Cell proliferation assays with two breast cancer cell lines
indicated that the mitomycin-C component, as well as the intact hybrid 1, retained potent
cytotoxic effects. The results indicated that although hybrid 1 was not selective for ER(+)-
MCF-7 cells as compared to ER(−)-MDA-MB-231 cells, the individual components within
the intact hybrid retained their biological properties. Although the objectives of maintaining
ER affinity and cytotoxic activity were achieved, synergy between the two components was
not established. The absence of cellular selectivity and lack of enhancement of toxicity
suggest that additional factors in hybrid design, such as modification of the linker or choice
of therapeutic group may be required. The synthetic steps needed to adapt the mitomycin C
component for conjugation make it less than optimal for such studies, particularly for
evaluation the effects of linker length and conformational flexibility. Nevertheless, this
seminal work provides the basis for defining the roles of the steroid component, the linker
properties and the therapeutic component. Studies related to those factors are in progress and
will be described in subsequent publications.
Experimental section
General information
All reagents and solvents were purchased from Aldrich or Fisher Scientific. THF and
toluene were distilled from sodium/benzophenone. Reactions were monitored by TLC,
performed on 0.2 mm silica gel plastic backed sheets containing F-254 indicator.
Visualization on TLC was achieved using UV light, iodine vapor and/or phosphomolybdic
acid reagent. Column chromatography was performed with 32–63 μm silica gel packing.
Melting points were determined using an Electrotherm capillary melting point apparatus and
are uncorrected. 1H NMR spectra were recorded with a Varian Mercury 300 MHz, a Varian
500 MHz or a Bruker 700 MHz spectrometer. DEPT and 13C experiments were performed
on a Varian Mercury instrument at 75 MHz. NMR spectra chemical shifts are reported in
parts per million downfield from TMS and referenced either to TMS, or internal standard for
chloroform-d, acetone-d6, methanol-d4, and THF-d8 solvent peak. Coupling constants are
reported in hertz. High-resolution mass spectra were obtained by electron impact (EI) or fast
atom bombardment (FAB) on MStation JMS700 (JEOL) by University of Massachusetts
Amherst, Mass Spectrometry Center using sodium iodide as an internal standard.
3,3,17,17-Diethylenedioxy-5,10-α-epoxy-estr-9(11)-ene 3 and 3,3,17,17-
diethylenedioxy-5,10-β-epoxy-estr-9(11)-ene 4—Estra-5-(10),9(11)-diene 3,17
diethylene ketal 2 (1 g, 2.79 mmol), hexafluoroacetone trihydrate (0.04 mL, 0.279 mmol),
pyridine (0.005 mL), 50% hydrogen peroxide (0.3 mL, 4.74 mmol, ca. 18 M) and
dichloromethane (10 mL) were charged into a round bottom flask at room temperature under
argon atmosphere. The mixture was stirred for 20 h at room temperature (TLC monitoring:
ethyl acetate: hexanes, 3: 7). After reductive workup (aqueous sodium thiosulfate solution, 2
g in 50 mL of water), the organic layer was washed with water (25 mL × 2), extracted with
dichloromethane (30 mL × 2). The organic layer was dried over magnesium sulfate and
concentrated under reduced pressure to give a mixture of 3 and 4 (ratio of α: β ≈ 3: 1, 1H
NMR). The mixture was purified from other components by chromatographic separation on
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a silica gel column (25 g, ethyl acetate: hexanes, 1: 4). The combined fractions containing
the products were concentrated under reduced pressure.
Yield = 0.81 g, 76%. Rf = 0.4 (ethyl acetate–hexanes 5: 1). 1H NMR (300 MHz, CDCl3, δ
6.05 (m, 1H, 3), 5.86 (m, 1H, 4), 0.88 (s, 3H, 3), 0.89 (s, 3H, 4). 13C NMR (75 MHz,
CDCl3) δ 191.1, 164.9, 132.2, 114.5, 55.8.
11β-(4-Hydroxyphenyl)estra-4,9-diene-3,17-dione 5 (one pot reaction)—
Copper(I) chloride (35 mg, 0.35 mmol) was added at room temperature to a ca. 1 M solution
of 4-(trimethylsilyloxy)-phenyl magnesium bromide in THF (10 mL) under argon
atmosphere. solution of the mixture of 3 and 4 (ratio ≈ 3: 1) (760 mg, 2.03 mmol) in THF
(10 mL) was added during ~30 min at room temperature (exothermic). The mixture was then
stirred for 1 h at room temperature (TLC monitoring: ethyl acetate: hexanes = 3: 7). When
the reaction was complete, the solution was poured into a biphasic mixture of aqueous
ammonium chloride (15 equiv, 6 mL) and methylene chloride (8 mL) at 10–15 °C. The
organic layer was separated, washed with water (20 mL × 2), concentrated the total volume
to ~5 mL, and diluted with methylene chloride (5 mL). Aqueous hydrochloric acid (6 equiv,
0.47 g in 2.6 mL of water) was added at 0–5 °C. This biphasic mixture was stirred for 2 h at
0–5 °C (pH < 1, pH paper) and then diluted with water (20 mL). The organic phase was
separated, washed with water (20 mL × 2) and carefully neutralized to pH ≈ 8 (10% sodium
bicarbonate, ~1.5 mL, pH ~ 7–8). The neutralized solution was washed with water (30 mL ×
2). The combined organic layer was dried over magnesium sulfate. Compound 5 (0.66 g,
90%) was isolated from a silica gel flash column chromatography (ethyl acetate–hexanes, 3:
7).
Yield = 0.66 g, 90%. 1H NMR (300 MHz, CDCl3, δ 6.75 and 7.07 (AA′BB′, 4H), 5.81 (s,
1H), 4.35 (d, J = 7.2 Hz, 1H), 4.01 (t, J = 6 Hz, 2H), 2.85 (t, J = 6 Hz, 2H), 2.63 (q, J = 7 Hz,
4H), 0.56 (s, 3H). 13C NMR (75 MHz, CDCl3,): δ 219.3, 200.0, 156.6, 154.3, 145.6, 135.8,
130.2, 128.2, 123.5, 115.9, 50.8, 47.9, 39.8, 38.2, 38.0, 36.9, 35.6, 31.1, 26.9, 26.0, 22.1,
14.6.
Triethylene glycol ditosylate 6—To a solution of triethylene glycol (3 g, 0.02 mol) in
diethyl ether (40 mL), triethylamine (7.8 g, 0.04 mol) was added at room temperature,
followed by addition of p-toluenesulfonyl chloride (7.8 g, 0.04 mol) under argon
atmosphere. The mixture was stirred at room temperature for 18 h (TLC monitoring, ethyl
acetate: hexanes, 1: 4). The organic solvents were removed under reduced pressure. The
residue was dissolved in methylene chloride (20 mL), washed with sodium bicarbonate (20
mL, saturated), water (20 mL × 2), brine (30 mL), dried over magnesium sulfate and
concentrated under vacuum. Colorless crystals of triethylene glycol ditosylate were obtained
from ethyl acetate.
Yield = 5.8 g, 64%. mp: 75–77 °C. Rf = 0.5 (ethyl acetate: hexanes, 1: 4). 1H NMR (300
MHz, CDCl3): δ 7.78 and 7.34 (AA′BB′, 8H), 4.12 (d, 4H), 3.65 (t, 4H), 3.53 (s, 4H), 2.45
(s, 6H). 13C NMR (75 MHz, CDCl3, δ 145.1, 133.3, 130.1, 128.2, 70.9, 69.4, 69.0, 21.8.
11β-(4-((2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-estra-4,9-diene-3,17-dione
7—To a solution of 5 (150 mg, 0.41 mmol) in acetonitrile (20 mL), potassium carbonate
(230 mg, 1.64 mmol) was added, and the mixture was heated at ~90 °C for 30 min. The bis
α,ώ-toluenesulfonyl triethylene glycol 6 (380 mg, 0.82 mmol) was charged and stirred at
~90 °C for 18 h (TLC monitoring: ethyl acetate: hexanes, 1: 1). The mixture was allowed to
cool to room temperature, and diluted with a mixture of methylene chloride (20 mL) and
cold water (~0 °C, 20 mL). After stirring for 30 min, the aqueous layer was extracted with
methylene chloride (30 mL × 2). The combined organic layers were washed with water (20
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mL), brine (20 mL), dried over magnesium sulfate and concentrated to dryness under
vacuum. The intermediate (50 mg, 19% yield) was isolated through a silica gel column (50
g) chromatography (ethyl acetate: hexanes, 2: 3).
Yield = 50 mg, 19%. Rf = 0.4 (ethyl acetate: hexanes = 1: 1). 1H NMR (300 MHz, CDCl3,):δ 7.79 and 7.33 (AA′BB′, J = 7.8 Hz, J = 8.1 Hz, 4H), 7.33 and 6.83 (AA′BB′, J = 7.1, J =
8.7 Hz, 4H), 5.79 (s, 1H), 4.38 (d, J = 6.6 Hz, 1H), 4.13 (t, J = 10.2 Hz, 2H), 4.08 (t, J = 4.8
Hz, 2H), 3.82 (t, J = 3.3 Hz, 2H), 3.69 (t, J = 3.3 Hz, 2H), 3.65 (m, 2H), 3.62 (m, 2H), 0.55
(s, 3H). 13C NMR (75 MHz, CDCl3,): δ 219.0, 199.4, 157.2, 156.1, 145.1, 145.0, 136.3,
133.3, 130.3, 130.0, 128.2, 128.1, 123.6, 115.0, 71.0, 70.9, 70.0, 69.4, 69.0, 67.6, 57.4, 57.1,
50.9, 47.9, 39.8, 38.2, 37.0, 35.6, 27.0, 26.1, 22.1, 21.8, 14.6.
To a solution of the intermediate (59 mg, 0.1 mmol) in 95% ethanol (5 mL), sodium azide
(13 mg, 0.2 mmol) was added. The mixture was stirred at ~90 °C for 18 h, and then
evaporated to dryness under reduced vacuum. Compound 7 was isolated using silica gel
column chromatography (ethyl acetate: hexanes, 2: 3).
Yield = 35 mg, 67%. 1H NMR (300 MHz, CDCl3): δ 7.08 and 6.84 (AA′BB′, J = 8.7 Hz, J
= 9.0 Hz, 4H), 5.80 (s, 1H, C4–H), 4.38 (d, J = 6.6 Hz, 2H, C11α–H), 4.10 (t, J = 4.8 Hz,
2H), 3.86 (t, J = 5.4 Hz, 2H), 3.74 (m, 2H), 3.68 (m, 2H), 3.39 (t, J = 5.1 Hz, 2H), 0.55 (s,
3H, C18–CH3). 13C NMR (75 MHz, CDCl3): δ 219.0, 199.4, 157.2, 156.1, 145.1, 136.3,
130.3, 128.5, 123.6, 114.9, 71.1, 70.9, 70.3, 67.6, 50.9, 50.9, 47.9, 39.8, 38.2, 38.0, 37.0,
35.6, 31.1, 27.0, 26.1, 22.1, 14.6.
11β-(4-((2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)estradiol 8—To a solution of
7 (284 mg, 0.55 mmol) in methylene chloride (20 mL), acetic anhydride (0.05 mL, d = 1.080
g mL−1, 0.55 mmol) was added slowly under argon atmosphere at room temperature,
followed by acetyl bromide (169 mg, 1.375 mmol). The mixture was stirred at room
temperature for 5 h (TLC monitoring: ethyl acetate: hexanes, 1: 1) and then carefully poured
into an aqueous solution of sodium bicarbonate (50 mg in 10 mL ice-water). After stirring
for 15 h at room temperature, the mixture was diluted with methylene chloride (50 mL). The
organic layer was separated, washed with sodium hydroxide (1N, 25 mL × 2), water (25 mL
× 3, to pH ≈ 7), dried over magnesium sulfate, and concentrated to dryness under reduced
vacuum. The crude product (310 mg, 0.55 mmol) was dissolved in methanol (20 mL), and
cooled to ~0 °C in an ice-water bath. Potassium hydroxide (62 mg, 1.10 mmol) was added
under argon atmosphere. The mixture was stirred at 0 °C for 1.5 h (TLC monitoring: ethyl
acetate: hexanes, 1: 1). Without further work up and purification, sodium borohydride (50
mg, 1.32 mmol) was added, and stirred for additional 2.5 h at 0 °C (TLC monitoring: ethyl
acetate: hexanes, 1: 1). After removal of the solvent under reduced pressure, the residue was
diluted with methylene chloride (50 mL) and ice-water (50 mL). The aqueous layer was
extracted with methylene chloride (25 mL × 2). Combined organic layers were washed with
water (25 mL), dried over magnesium sulfate, and concentrated to dryness under reduced
vacuum. The purification step was performed using column chromatography (silica gel-ethyl
acetate: hexanes, 1: 1). Compound 8 was collected from combined fractions.
Yield = 148 mg, 56% (one pot reaction, three-steps combined). 1H NMR (300 MHz,
CDCl3): δ 6.63 (d, J = 4.8 Hz, 2H), 6.48 (d, J = 5.4 Hz, 1H), 6.29 (d, J = 5.1 Hz, 2H), 6.25
(d, J = 1.5 Hz, 1H), 6.08 (dd, J = 5 Hz, J = 1. 5 Hz, 1H), 4.00 (t, J = 2.7 Hz, 2H), 3.92 (t, 1H,
H-11α), 3.79 (t, J = 3.3 Hz, 1H), 3.70 (m, 3H), 3.65 (m, 4H), 1.77 (t, J = 3 Hz, 1H), 2.96 (t,
J = 9 Hz, 1H), 2.84 (s, 1H), 2.80 (d, J = 3 Hz, 1H), 2.49 (dd, J = 1.2 Hz, J = 7.7 Hz, 1H),
1.00–2.30 (m, 10H), 0.32 (s, 3H, C18–CH3) 13C NMR (75 MHz, CDCl3, δ155.9, 153.3,
137.9, 136.2, 130.8, 127.9, 115.5, 113.8, 113.5, 82.8, 71.0, 70.9, 70.3, 70.1, 67.3, 52.0, 50.9,
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47.6, 45.7, 43.8, 38.5, 35.6, 30.7, 30.4, 28.2, 23.4, 13.1. HRMS calcd for C30H39N3O5 m/z
521.2890, found m/z 521.2840.
N-Methyl mitomycin C 10 (porfiromycin)—To a reaction flask, mitomycin C 9 (200
mg, 0.6 mmol), K2CO3 (0.83 g, 6 mmol), and anhydrous acetone (30 mL) were charged at
room temperature under argon; then methyl iodide (0.75 mL, 1.2 mmol) was added to the
mixture. The mixture was heated at reflux for 16 h (TLC monitoring: methanol:
dichloromethane = 1: 9). When the reaction was complete, the mixture was cooled to room
temperature, filtered, and washed with a small volume of anhydrous acetone. The filtrate
was concentrated to dryness (470 mg). The crude product was purified using column
chromatography (silica gel, 10 g, methanol: dichloromethane = 10: 90). The combined
fractions containing the product were concentrated under reduced pressure to give 10.
Yield = 128 mg, 61%. Rf = 0.4 (methanol: dichloromethane = 10: 90). 1H NMR (300 MHz,
CDCl3) δ 6.43 (s, 1H), 5.01 (s, 2H), 4.63 (dd, J = 6 Hz, 1H), 4.26 (q, 2H), 3.51 (dd, J = 6
Hz, 1H), 3.44 (dd, J = 5 Hz, 1H), 3.21 (s, 3H), 4.63 (dd, J = 6 Hz, 1H), 2.20 (s, 3H). 13C
NMR (75 MHz, CDCl3,) δ 179.0, 176.0, 157.0, 155.7, 148.5, 109.6, 106.1, 103.7, 62.5,
49.8, 46.2, 43.3, 43.0, 42.7, 32.7, 9.8.
Preparation of 7-N-propargyl-N-methylmitomycin C 11 without purification of
intermediates
Methylation: To a reaction flask, mitomycin C 9 (200 mg, 0.6 mmol), potassium carbonate
(380 mg, 6 mmol, anhydrous, ~120 °C for 2 h), and acetone (30 mL, anhydrous) were
charged under argon, then methyl iodide (1.7 g, 0.75 mL d = 2.275 g mL−1, 12 mmol) was
added at room temperature under argon. The mixture was heated to reflux for 18 h (TLC
monitoring: methanol: dichloromethane = 1: 9, Rf = 0.4, reaction mixture; Rf = 0.1,
mitomycin C). When the reaction went to completion, the mixture was allowed to cool to
room temperature, then filtered, washed with small amount of anhydrous acetone. The
filtrate was evaporated to dryness. Weight of the intermediate compound was 341 mg.
Without further purification, the material was used for the next step.
Hydrolysis: A solution of the crude product (341 mg) in 0.1 N solution of sodium
hydroxide (30 mL) was stirred for 4 h at room temperature (TLC monitoring: methanol:
dichloromethane = 1: 9). One new spot (Rf = 0.3) was formed (Rf = 0.4, starting material) by
TLC analysis.
Acidification: The resultant mixture was allowed to cool to ~0 °C in an ice bath; then 1 N
sulfuric acid (~2.6 mL) was added dropwise to pH ~ 4. The acidified mixture was extracted
with ethyl acetate (20 mL × 3). The organic layer was separated, dried over magnesium
sulfate, and concentrated to dryness. Weight of the crude intermediate was 274 mg.
Methylation: The acidified crude intermediate in anhydrous diethyl ether (15 mL) was
allowed to cool to −10 °C to −15 °C (ice-sodium chloride). Diazomethane (gas) was passed
into the pre-cooled solution for 15 min, then the mixture was stirred for 4 h at ~0 °C (TLC
monitoring: methanol: dichloromethane = 1: 9). When the reaction was complete, the
mixture was allowed to warm to room temperature and concentrated to dryness under
reduced vacuum in a fume hood. During the drying process, the product was treated with
anhydrous methanol (10 mL × 3). Weight of the crude product was 218 mg.
7-Propargylaminomitosane formation: To a solution of the intermediate (218 mg) in
anhydrous methanol (12 mL), propargylamine (0.19 mL, 1 eq) was added at room
temperature under argon. The mixture was stirred at room temperature for 2 h (TLC
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monitoring: methanol: dichloromethane = 1: 9). The mixture was evaporated to dryness
under a reduced vacuum, treated with anhydrous methanol (10 mL × 3) during the
evaporation process. The crude product was isolated (298 mg) and subsequently purified
using column chromatography (silica gel, 10 g; methanol: dichloromethane = 15: 85). The
fractions containing the product were combined and concentrated under reduced pressure to
give the product 11.
Yield = 127 mg, 55%. (five-steps).
HRMS calcd for C19H22N4O5 m/z 386.1590, found m + 1/z 387.1662.
Steroidal antiestrogen-mitomycin C hybrid 1—To a reaction flask, compound 8 (7.5
mg, 0.0195 mmole) and compound 11 (10.1 mg, 0.0194 mmole) were suspended in a 1: 1
mixture of water and t-butyl alcohol (0.6 mL) (0.3 mL of water, 0.3 mL of t-butyl alcohol) at
room temperature. Copper(II) sulfate pentahydrate (0.01 eq, 1.9 × 10−4 mmol, 3 uL of
freshly prepared 0.065 M solution in water) was added, followed by sodium ascorbate (0.05
eq, 9.7 × 10−4 mmol, 4 uL of freshly prepared 0.25 M solution in water). The heterogeneous
mixture was stirred at room temperature for 18 h (TLC monitoring: methanol:
dichloromethane = 1: 9). To the mixture, ice (~1 g) was added and stirred for 5 min, then
extracted with dichloromethane (5 mL × 3). The organic layer was separated, dried over
magnesium sulfate, and concentrated under reduced vacuum. The crude product was
purified through a silica gel column (10 g) chromatography (methanol: dichloromethane = 1:
9). The combined fractions containing the product were concentrated under reduced pressure
to give a white solid 1.
Yield = 14.4 mg, 82%. 1H NMR (CDCl3, δ 7.67 (s, 1H), 6.94 (d, J = 8.4 Hz, 2H) 6.74 (d, J
= 8.7 Hz, 1H), 6.61 (d, J = 9 Hz, 2H), 6.55 (d, J = 2.4 Hz, 1H), 6.51 (d, J = 6.6 Hz, 1H), 6.33
(dd, J = 2.4 Hz, J = 8.3 Hz, 1H), 6.29 (s, br, 1H), 4.80 (br, 2H), 4.69 (q, 3H), 4.63 (d, J = 4.5
Hz, 1H), 4.47 (t, J = 4.5 Hz, 2H), 4.36 (t, J = 10.5 Hz, 1H), 4.25 (d, J = 13.2 Hz, 1H), 4.01 (t,
J = 4.2 Hz, 1H), 3.90 (t, J = 5.4 Hz 1H), 3.81 (t, J = 5.1 Hz, 1H), 3.75 (t, J = 4.8 Hz, 1H),
3.67 (d, J = 8.1 Hz, 1H), 3.63 (d, J = 3.6 Hz, 1H), 3.58 (d, J = 3.6 Hz, 1H), 3.53 (d, J = 4.5
Hz, 1H), 3.45 (dd, J = 1.8 Hz, J = 13.2 Hz, 1H), 3.16 (s, 3H, OCH3), 2.94 (d, J = 12.9 Hz,
1H), 2.81 (d, J = 14.7 Hz, 2H), 2.48 (d, J = 13.5 Hz, 1H), 2.0–1.0 (see COSY, appendix),
2.25 (s, 3H, CH3), 1.92 (s, 3H, CH3), 0.31 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3,
Appendix: Fig. 90, 91, 92) δ 179.5, 176.3, 156.8, 155.8, 155.2, 153.6, 147.0, 145.0, 137.9,
136.5, 130.9, 130.4, 127.8, 123.3, 115.6, 113.7, 113.5, 110.2, 106.2, 105.0, 82.8, 70.8, 70.0,
69.5, 67.5, 62.8, 52.0, 50.6, 49.9, 49.8, 47.5, 46.4, 45.7, 43.9, 43.3, 43.0, 42.8, 41.0, 38.6,
35.7, 30.6, 30.4, 28.2, 13.1, 9.9. HRMS calcd. for C49H61N7O10 m/z 907.4480, found m/z
907.4445; 1D NOESY; COSY spectra are shown in ESI†
Biological assays
Competitive binding to human LBD-ERα and human LBD-ERα ERβ—Binding
affinities of the steroidal derivatives relative to E2 were performed in incubations with the
LBD of ERα in lysates of Escherichia coli in which the LBD of human ERα (M250–V595).
The assay was performed overnight in phosphate buffered saline + 1 mM EDTA at room
temperature. The competition for binding of [3H]E2 to the LBD of the E2-derivatives in
comparison to E2, relative binding affinity (RBA) was determined over a range of
concentrations from 10−12 to 10−6 M. After incubation, the media is aspirated, the plates are
washed 3 times and the receptor bound radioactivity absorbed to the plates are extracted
with methanol and counted. The results, as RBAs compared to E2, of all receptor studies are
from at least 3 separate experiments performed in duplicate. RBAs represent the ratio of the
EC50 of E2 to that of the steroid analog × 100 using the curve fitting program Prism to
determine the EC50.
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Estrogenic potency in Ishikawa cells—The potency of the anti-estrogen-mitomycin C
hybrid 1 was determined in an estrogen bioassay, the induction of alkaline phosphatase in
human endometrial adenocarcinoma cells (Ishikawa) grown in 96-well microtiter plates. The
cells are grown in phenol red free medium with estrogen depleted (charcoal stripped) bovine
serum in the presence or absence of varying amounts of the steroids, across a dose range of
at least 6 orders of magnitude. After 3 days, the cells are washed, frozen and thawed, and
then incubated with 5 mM p-nitrophenyl phosphate, a chromogenic substrate for the alkaline
phosphatase enzyme, at pH 9.8. To ensure linear enzymatic analysis, the plates are
monitored kinetically for the production of p-nitrophenol at 405 nm. For antagonists, the
effect (Ki) of each compound tested at a range of 10−6 M to 10−12 M was measured for the
inhibition of the action of 10−9 M E2 (EC50–0.2 nM). Each compound was analyzed in at
least 3 separate experiments performed in duplicate. The Ki and RSA (RSA = ratio of 1/
EC50 of the steroid analog to that of E2 × 100) were determined using the curve fitting
program Prism.
Cell proliferation assays—Measurement of the toxicity of 1 toward MCF-7 (ER+) and
MDA-MB231 (ER−) cell lines. Toxicity experiments were performed on breast cancer cell
lines MCF-7 and MDA-MB231 obtained from the American Type Culture Collection. Both
cell lines were grown in Minimal Essential Media (MEM) containing phenol red (GIBCO
BRL, Rockville, MD) supplemented with 10% fetal bovine serum (Biowhittaker,
Walkersville, MD), 2 mM glutamine and 1 mM sodium pyruvate in a 5% CO2/95% air
atmosphere. Cells were seeded at 2 × 105 in 6-well plates and, 48 h later, exposed to test
compounds in growth medium for 2 h. After treatment, cells were washed once and
incubated in fresh growth medium for 24 h, after which they were trypsinized and replated
at 103 cells per 6 cm dish. After 11 days, colonies were fixed with acetic acid/methanol and
stained with GIEMSA stain and counted.
Supplementary Material
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Fig. 1.
Representative estradiol-based ER-targeted hybrids substituted at 3, 16α, 17α or 17β
position.10,13,19
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Fig. 2.
Preparation of a 7α-substituted estradiol-chlorambucil hybrid.32
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Fig. 3.
Mitomycin C and structural modifications that retain anti-tumor activity.50,51
Hanson et al. Page 16
Org Biomol Chem. Author manuscript; available in PMC 2013 November 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
7-N-Propargyl-N′-methyl mitomycin C (N-propargyl porfirimycin) linked to 11β-(4-
alkoxyphenyl) estradiol antiestrogen through an triethylene glycol linker to give target
hybrid 1. Linkage avoids detrimental interactions with target proteins (estrogen receptor) or
DNA intercalation sites.
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Scheme 1.
Preparation of the 11β-[4-(ώ-azido-triethyleneglycoloxy)-phenyl]estradiol. Reagents and
conditions (a) CF3COCF3, H2O2, pyridine, rt; (b) [1] Cu(I), [2] HCl; (c) [1] 6, K2CO3,
CH3CN, reflux, [2] NaN3, ethanol, reflux; (d) [1] AcBr, Ac2O, CH2Cl2, rt, [2] KOH,
methanol, 0–5 °C, [3] NaBH4, KOH, methanol.
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Scheme 2.
Preparation of the mitomycin C component. Reagents and conditions (a) CH3I, K2CO3,
acetone, reflux; (b) [1] 0.1 N NaOH, rt, [2] 1 N H2SO4, 0 °C, [3] CH2N2, ether, [4]
propargylamine, methanol, rt.
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Scheme 3.
Ligation of mitomycin C and estradiol components to form target hybrid 1. Reagents and
conditions (a) 0.02 eq CuSO4·5H2O, 0.10 eq sodium ascorbate, H2O-tert-BuOH (1: 1), rt, 20
h.
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